Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 2

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 2
---
 of the outstanding shares of Telomir Common Stock, on non-fully diluted basis. When taking into account the issuance of the Warrants, 41% of the outstanding shares of TELI Common Stock and the pre-Merger equity holders of TELI are expected to hold approximately 59% of the outstanding shares of Telomir Common Stock, on a fully-diluted basis.

Shares of TELO Common Stock are currently listed on The Nasdaq Global Market under the symbol “TELO.” The post-Merger company will continue to trade on the Nasdaq under the symbol “TELO”. On November 19, 2025, the closing sale price of the Telomir Common Stock was $1.43 per share.

After careful consideration, TELO’s board of directors has unanimously (i) determined that the Merger and the other transactions and actions contemplated by the Merger Agreement (the “Contemplated Transactions”) are fair to, advisable and in the best interests of TELO and its stockholders; (ii) approved and declared advisable the Merger Agreement and the Contemplated Transactions, including the issuance of shares of Telomir common stock to the stockholders of TELI; and (iii) determined to recommend, upon the terms and subject to the conditions set forth in the Merger Agreement and based on the current business of Telomir, that the stockholders of Telomir vote “ FOR” Proposal Nos. 1, 2, 3, 4, 5, 6 and 7. More information about Telomir, TELI and the proposed transaction is contained in the accompanying proxy statement. Telomir urges you to read the accompanying proxy statement carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER “ RISK FACTORS” BEGINNING ON PAGE 14.

Telomir is excited about the opportunities the Merger brings to its stockholders, and thanks you for your consideration and continued support.

Sincerely,

Erez Aminov

Chief Executive Officer

Telomir Pharmaceuticals, Inc.

November , 2025

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved the Merger described in this proxy statement or the Telomir Common Stock to be issued in connection with the Merger or passed upon the adequacy or accuracy of this proxy statement.

The accompanying proxy statement is dated , 2025, and, together with the enclosed form